Palatin Technologies Inc
LSE:0KF3

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
LSE:0KF3
Watchlist
Price: 0.093 USD -1.9%
Market Cap: 2.6B USD

Palatin Technologies Inc
Investor Relations

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector.

Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

Show more
Loading

Earnings Calls

2025 Q2
May 7, 2025
Show Transcript
Previous
Next
Skyworks Achieves Strong Q2 2025 Results, Focused on Growth and Shareholder Returns
2025 Q2
May 7, 2025

In Q2 2025, Skyworks reported revenues of $953 million and earnings per share of $1.24, exceeding expectations. Although mobile revenue experienced a 17% sequential decline, broad market offerings grew 2% sequentially. The gross margin was robust at 46.7%. The company generated $371 million in free cash flow, returning a record $600 million to shareholders through dividends and share buybacks. Looking forward, anticipated revenue for Q3 is between $920 million and $960 million, with mobile expected to decline slightly, while broad markets are projected to continue their growth trajectory. Skyworks remains focused on innovation, particularly in automotive and IoT sectors.

Show Full Analysis

Management

Dr. Carl Spana Ph.D.
Co-Founder, President, CEO & Director
No Bio Available
Mr. Stephen T. Wills CPA, MST
CFO, COO, Executive VP, Treasurer & Secretary
No Bio Available
Burns McClellan
Vice President of Investor Relations
No Bio Available
Mr. Stephen A. Slusher Esq.
Chief Legal Officer
No Bio Available
Dr. Michael B. Raizman M.D.
Chief Medical Officer
No Bio Available
Mr. James E. Hattersley
Senior Vice President of Business Development
No Bio Available
Mr. John Dodd Ph.D.
Senior Vice President of Preclinical Development
No Bio Available
Mr. Robert Jordan
Senior Vice President of Program Operations
No Bio Available

Contacts

Address
NEW JERSEY
Cranbury
4B Cedar Brook Drive
Contacts
+16094952200.0
www.palatin.com